Aspen launches novel ARV Combination: Set to further improve treatment options

Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option.

EmdoltenTM, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will be available in 50mg, 300mg/300mg dosage strengths.

Stavros Nicolaou, Aspen Senior Executive, Strategic Trade, said, “There has been significant excitement at a clinician, funder and patient level about the use of Dolutegravir, a second generation integrase inhibitor, which offers clinical and safety profile benefits. EmdoltenTM enhances Aspen’s HIV product offering in South Africa and has the potential to improve the lives of millions of South Africans presently on ARV treatment. As part of our ARV leadership, we were able to introduce the first Dolutegravir and Dolutegravir-containing combinations into the South African market over 18 months ago.  This represents a further refinement of Dolutegravir-containing combinations.”

“Aspen pioneered the development and manufacture of generic ARVs in South Africa in the early 2000s, when our country was grappling with HIV denial and the potentially destructive consequences of an un-arrested HIV pandemic.  Prior to this, ARV’s, which were then patent protected, were inaccessible to the majority of these patients.”

Aspen’s pioneering efforts resulted in the accelerated introduction of South Africa’s public ARV programme which has contributed to the successful treatment of hundreds of thousands of patients afflicted with HIV and AIDS.

“Since the launch of Aspen Stavudine, our first generic ARV in August 2003, we have continued to be an anchor supplier of ARVs to both the South African public and private sectors, a leadership position we have maintained through extensive manufacturing investment into the local economy and the introduction of an ongoing pipeline of ARV products. This has enabled Aspen to bring the latest ARV innovations to market, providing patients and healthcare professionals with the most advanced ARV treatment options for patients’ specific needs,” added Nicolaou.

Issued by:

Shauneen Beukes, Aspen Group Communications Manager

Tel: +27 12 6618467 Cell: 082 389 8900

On Behalf Of:

Stavros Nicolaou, Senior Executive, Aspen Pharmacare Holdings Ltd

Cell: 082 458 3135

我们的使命

更多详情

致力于提高患者的生命健康和质量

我们的愿景

更多详情

作为一个负责任的企业公民,在全球提高优质和患者可及的药物,传递我们的价值。

我们的价值观

更多详情

我们的价值观是爱施健存立和发展的基石。集团上下以此为指引,为实现集团目标而共同奋斗。

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.